Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD

Next Previous
X
Search
Trial Profile

A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms FLAME
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 22 May 2019 Results assessing cost-effectiveness analysis of Indacaterol/Glycopyrronium (Ind/Gly) vs Salmeterol/Fluticasone (Sfc) as Maintenance Treatment for Copd Patients in Taiwan, presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 19 Sep 2018 Results assessing Early Clinically Important Improvement (ECII) and exacerbation outcomes in Chronic-obstructive-pulmonary-disease patients, presented at the 28th Annual Congress of the European Respiratory Society.
    • 18 Jul 2018 Results of sub analysis of FLAME published in the American Journal of Respiratory and Critical Care Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top